Opinion|Videos|December 10, 2024
Vowst as a Potential Option for Patients With Recurrent C Difficile Infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
- Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the mechanism of action of Vowst, and how does this therapy differ from previously used therapies in recurrent C difficile infections?
- What is the key data that led to the FDA-approval of Vowst for recurrent C difficile infection?
- Who are the target patient populations for Vowst?
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.
An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.
Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Risankizumab Outperforms Deucravacitinib in Moderate Plaque Psoriasis
5